On Monday shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) closed at $12.88. Company’s sales growth for last 5 years was 117.70% and EPS growth for next 5 years is recorded as 5.60%. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that it will present preclinical and clinical data showcasing its deep oncology pipeline at the 2015 American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia.
Alcatel Lucent SA (ADR) (NYSE:ALU) has institutional ownership stands at 4.70%. In last trading activity company’s stock closed at $4.35. Nokia is set on acquiring Alcatel-Lucent SA (ADR) (NYSE:ALU)’s wireless business and is already in advanced talks with the rival company about a potential deal.
On last trading day Popular, Inc. (NASDAQ:BPOP) moved up 0.31% to close at $35.08. Its volatility for the week is 1.39% while volatility for the month is 2.01%. BPOP’s sales growth for past 5 years was -2.50% and its EPS growth for past 5 years was -21.60%. Popular, Inc. (NASDAQ:BPOP) monthly performance is -0.71%. In the latest statement by the brokerage house, UBS downgrades its outlook on Popular, Inc. (NASDAQ:BPOP). The current rating of the shares is Neutral, according to the research report released by the firm. Previously, the company had a rating of Buy.
Esterline Technologies Corp. (NYSE:ESL) has 0.40% insider ownership while its institutional ownership stands at 26.10%. In last trading activity company’s stock closed at $115.42. On 1 April, Esterline Corporation (NYSE: ESL) has announced the selection of Julie Albrecht to serve as the company’s Senior Director, Investor Relations and Treasurer. In her investor relations role, Albrecht succeeds Brian Keogh who is retiring after 31 years with the company.
On last trading day Pfizer Inc. (NYSE:PFE) fell -0.99% to close at $35.09. Its volatility for the week is 1.48% while volatility for the month is 1.55%. PFE’s sales growth for past 5 years was 0.10% and its EPS growth for past 5 years was 3.10%. Pfizer Inc. (NYSE:PFE) monthly performance is 3.21%. Pfizer Inc. (NYSE:PFE) announced the launch of a new competitive grants programme the company is funding to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease.